New combo aims to revive immunotherapy in resistant cancers
Disease control
Recruiting now
This early-phase study tests a new drug (PLN-101095) alone and with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 124 participa…
Phase: PHASE1 • Sponsor: Pliant Therapeutics, Inc. • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC